Monte Rosa Therapeutics, Inc. (GLUE) Stock Price & How to Invest

Last updated November 2026

Short answer

GLUE is Monte Rosa Therapeutics, a Boston-based clinical-stage biotech pioneering molecular glue degraders (drugs that redirect the body's protein-disposal machinery to destroy disease-driving proteins). It is a pre-product, catalyst-and-partnership story: its value rests on trial readouts and two large Novartis deals rather than on product sales. As of November 20, 2026 the stock closed near $8.71, down about 43% year to date and about 36% over one year, for a market value near $744 million.

GLUE stock price

As of 2026-11-20, Monte Rosa Therapeutics, Inc. (GLUE) last closed at $8.64, down 39.2% over the past year. Over the past 52 weeks it has traded between $8.64 and $25.31.

GLUE last close
$8.64
1 day
-3.03%
1 month
-22.99%
1 year
-39.24%
52-week range
$8.64 to $25.31
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Monte Rosa Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.

GLUE key stats

At $8.64 on November 20, 2026, Monte Rosa Therapeutics, Inc. (GLUE) has a market cap of $738M.

Market cap
$738M
Price to book
1.5
Beta
1.38

Market cap, P/E and yield are measured at the $8.64 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Monte Rosa Therapeutics, Inc. (GLUE)?

The last two weeks for Monte Rosa Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • GLUE closed at $8.64 on November 20, 2026, down 7.8% over the past five trading days (from $9.37).

Monte Rosa Therapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Monte Rosa Therapeutics, Inc. (GLUE) do?

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), small molecules that recruit the cell's natural ubiquitin-proteasome system to selectively eliminate target proteins that are otherwise hard to drug. Its QuEEN discovery engine pairs AI-guided chemistry with structural biology and proteomics to design these degraders. The pipeline centers on three programs: MRT-6160 (a VAV1-directed degrader for immune-mediated diseases, licensed to Novartis), MRT-8102 (a NEK7/NLRP3-pathway degrader for inflammatory and cardiovascular disease that posted positive interim Phase 1 data in January 2026 and full GFORCE-1 Phase 1 results in October 2026), and MRT-2359 (a MYC-pathway degrader in oncology).

As a clinical-stage company, Monte Rosa has no approved products and generates revenue mainly from collaboration and license payments rather than drug sales, so it runs a large net loss. The investment picture is shaped by two Novartis agreements (a 2024 deal for MRT-6160 with $150M upfront and up to $2.1B in milestones, and a broader 2025 immunology and inflammation pact adding $120M upfront and up to $5.4B in potential milestones), a $50 million milestone triggered in September 2026 when Novartis started a Phase 2 study of MRT-6160 in Sjogren's disease, a further $37.5 million milestone triggered in October 2026 by the first patient visit in a Phase 2a/b study in psoriatic arthritis, cash and investments of about $583 million at the end of September 2026 (the company says its runway extends into 2029), and binary clinical catalysts. Third-quarter 2026 results, reported November 5, showed collaboration revenue of about $54.4 million (up from about $12.8 million a year earlier, mostly the $50 million milestone) and net income of about $3.1 million, versus a $27.1 million loss a year earlier; EPS of $0.03 compared with the roughly -$0.20 analysts expected. Over the last twelve months revenue was about $70 million and the net loss about $131 million. Analysts still expect losses of about $1.02 per share for 2026 and $1.74 for 2027 as milestone income is lumpy. In November the company presented preclinical data at ACR Convergence 2026 on MRT-8102 in gout. It is a higher-risk, platform-and-pipeline holding whose price swings on data and deal news.

What's driving Monte Rosa Therapeutics, Inc. (GLUE)?

1. Novartis partnerships

Two Novartis agreements validate the platform and fund it: a 2024 license for VAV1-directed MRT-6160 (about $150M upfront plus up to roughly $2.1B in milestones) and a broader 2025 immunology and inflammation deal (about $120M upfront plus up to roughly $5.4B in milestones). These deals supply non-dilutive cash and milestone upside if partnered programs advance. In September 2026 Novartis started Phase 2 studies of MRT-6160 in Sjogren's disease and psoriatic arthritis, triggering a $50 million milestone payment to Monte Rosa. In October 2026 the first patient visit in the psoriatic arthritis Phase 2a/b study triggered a further $37.5 million milestone, which will be recorded after the third quarter.

2. MRT-8102 in inflammation and cardiovascular disease

The NEK7-directed degrader MRT-8102 showed profound CRP reductions in an interim Phase 1 readout in January 2026, and full GFORCE-1 results released October 1, 2026 showed 88% of treated subjects with elevated cardiovascular risk reaching CRP below 2 mg/L by week four, with NEK7 degradation of about 80% to 90% and no serious adverse events. Next steps are a roughly 160-patient Phase 2b (GFORCE-2) in coronary artery disease planned for the first half of 2027, a gout study (GEMINI-1) expected to start in the fourth quarter of 2026 with initial data in the second half of 2027, and a hidradenitis suppurativa study (GALAXY-1) in the first half of 2027.

3. QuEEN platform breadth

The QuEEN discovery engine is designed to generate new molecular glue degraders against historically undruggable targets. A productive platform can seed additional wholly owned programs and further partnering deals, spreading risk across multiple shots rather than a single asset. A next-generation NEK7 degrader, MRT-9347, is expected to enter a first-in-human study.

4. Oncology optionality with MRT-2359

MRT-2359 targets MYC-driven cancers, including a planned signal-confirming study in AR-mutant castration-resistant prostate cancer. It adds an oncology dimension to a pipeline otherwise weighted toward immunology and inflammation. An update from the enzalutamide Phase 1/2 expansion arm is expected by the end of 2026, and a data update from the MODeFIRe-1 Phase 2 study with apalutamide in AR-mutant metastatic castration-resistant prostate cancer is expected in 2027.

What are the risks to Monte Rosa Therapeutics, Inc. (GLUE)?

Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. Molecular glue degraders remain a relatively young modality, and early positive biomarker data (such as CRP reductions) do not guarantee later-stage clinical or regulatory success. Much of the company's headline value comes from Novartis milestone potential that is contingent and may never be earned. The stock is volatile and can move sharply on single data points, and future capital raises could dilute shareholders. Competition in targeted protein degradation is intensifying across both large pharma and specialized biotechs. The shares fell about 40% over the three months to November 20, 2026 and about 20% in the past month, to near their 52-week low of about $8.63, even after the positive GFORCE-1 readout and two Novartis milestones, showing how sentiment can move independently of reported biomarker data. Partner income is lumpy: the third-quarter profit came almost entirely from a single $50 million milestone, and analysts expect revenue of under $4 million in the first quarter of 2027.

What is the Monte Rosa Therapeutics, Inc. (GLUE) forecast?

8 analysts publish price targets on GLUE, averaging $25.38 as of November 2026, or +193.7% against the $8.64 share price on November 20, 2026. The published targets run from $15.00 to $37.00, a wide spread, and the ratings split 10 buy, 0 hold, 0 sell. Over the last six months there has been 1 raise and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GLUE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is GLUE a buy or a sell?

We give no verdict on Monte Rosa Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Novartis partnerships. Two Novartis agreements validate the platform and fund it: a 2024 license for VAV1-directed MRT-6160 (about $150M upfront plus up to roughly $2.1B in milestones) and a broader 2025 immunology and inflammation deal (about $120M upfront plus up to roughly $5.4B in milestones). The most optimistic published target, $37.00, assumes this works close to its best case.

The case against. Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. The most pessimistic target, $15.00, is roughly what GLUE is worth if this bites instead.

Read the full bull and bear case on GLUE, including what would have to change to break either one. Walnut is not an investment adviser.

Has Monte Rosa Therapeutics, Inc. (GLUE) split its stock?

No. Monte Rosa Therapeutics, Inc. (GLUE) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Monte Rosa Therapeutics, Inc. (GLUE) valued?

Market cap, P/E and dividend yield at today's price are in the GLUE key stats above. The business figures below come from Monte Rosa Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$70M (collaboration income)
  • Net loss (TTM): ~-$131M
  • Q3 2026 EPS: ~$0.03 vs ~-$0.20 expected
  • Cash and investments: ~$583M at September 30, 2026

As of November 2026: Revenue is collaboration and license income (largely Novartis-related), not product sales, and it varies with deal timing; the October 2026 $37.5 million Novartis milestone falls after the September figures. Standard valuation multiples like P/E do not apply to a pre-profit biotech; with cash near $583 million against a market value around $744 million, the market is pricing relatively little platform value. The average target from eight analysts is about $25, roughly three times the November 20 close.

Who competes with Monte Rosa Therapeutics, Inc. (GLUE)?

Targeted protein degradation biotechs

Companies focused on degraders and molecular glues, such as Arvinas, Kymera Therapeutics, Nurix Therapeutics, and C4 Therapeutics, compete for targets, talent, and pharma partnerships in the same modality.

Large pharma degrader programs

Big pharmaceutical companies including Novartis (also a Monte Rosa partner), Bristol Myers Squibb, and Pfizer run internal degrader efforts, making them simultaneously potential collaborators and competitors.

Anti-inflammatory and immunology developers

In the specific indications Monte Rosa targets, established immunology and cardiovascular-inflammation therapies (including NLRP3 and IL-1/IL-6 pathway drugs from other developers) compete for the same patient populations.

What stocks are similar to Monte Rosa Therapeutics, Inc. (GLUE)?

Other names that sit close to GLUE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Monte Rosa Therapeutics, Inc. (GLUE)

There are three common ways to get GLUE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so GLUE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GLUE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa is a well-capitalized platform biotech whose stock tracks clinical data and Novartis milestones, not current earnings. With about $583 million of cash and investments at the end of September 2026 (before a further $37.5 million Novartis milestone earned in October) against a market value near $744 million after a sharp 2026 decline, the market is assigning modest value to the pipeline beyond its cash. A $50 million milestone made the third quarter its first profitable one in the past year.

More on Monte Rosa Therapeutics, Inc. (GLUE)

Whether GLUE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GLUE a buy or a sell?, and where the stock could go from here in the GLUE stock forecast.

For income investors, whether GLUE pays a dividend and how the payout looks is covered in does GLUE pay a dividend? And to weigh GLUE against a peer, read the full side-by-side comparisons: GLUE vs NRIX and GLUE vs NVS.

Wondering how GLUE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Monte Rosa Therapeutics, Inc.

Ask Walnut's AI anything about GLUE and see how it fits what you own.

FAQ

What does Monte Rosa Therapeutics do?

+

It is a clinical-stage biotech developing molecular glue degraders, small molecules that use the body's natural protein-disposal system to selectively destroy disease-causing proteins. Its lead programs target immune-mediated, inflammatory, cardiovascular, and cancer conditions.

Why does GLUE have revenue if it has no approved drugs?

+

Its revenue comes mainly from collaboration and license payments, especially upfront and milestone payments from Novartis, rather than from selling drugs. That revenue can be lumpy and does not reflect commercial product sales.

What are the Novartis deals worth to Monte Rosa?

+

A 2024 license for MRT-6160 carried about $150M upfront and up to roughly $2.1B in milestones, and a broader 2025 immunology and inflammation agreement added about $120M upfront and up to roughly $5.4B in potential milestones. Most milestone value is contingent on future progress.

Is Monte Rosa profitable?

+

No, although one quarter was. As of November 2026 it reported a trailing net loss of roughly $131M, even though a $50 million Novartis milestone produced a small third-quarter 2026 profit of about $3.1M. Like most clinical-stage biotechs, it spends heavily on research and development ahead of any product approval, and analysts expect a loss of about $1.74 per share in 2027.

How much cash does GLUE have?

+

The company reported roughly $583M in cash, cash equivalents, restricted cash and marketable securities at the end of September 2026, down from about $626M at the end of June, before a $37.5M Novartis milestone triggered in October 2026. It has said its cash is expected to fund operations into 2029, reducing near-term financing pressure.

What are the key upcoming catalysts?

+

Watched events include the start of the MRT-8102 GEMINI-1 gout study (expected in the fourth quarter of 2026, with initial data in the second half of 2027), the Phase 2b GFORCE-2 study in coronary artery disease and the GALAXY-1 hidradenitis suppurativa study (both planned for the first half of 2027), Novartis's two Phase 2 studies of MRT-6160 (started in 2026), first-in-human dosing of MRT-9347, an MRT-2359 enzalutamide-arm update by year-end 2026 and a MODeFIRe-1 data update in 2027. Data and deal news tend to drive the stock.

What are the main risks with GLUE?

+

It is pre-product and unprofitable, so clinical failures, regulatory setbacks, or the loss of Novartis milestones would hurt significantly. The stock is volatile, the degrader modality is still maturing, and future capital raises could dilute shareholders.

Who competes with Monte Rosa?

+

Other degrader-focused biotechs such as Arvinas, Kymera, Nurix, and C4 Therapeutics, large pharma companies with internal degrader programs, and developers of competing anti-inflammatory and immunology therapies in its target indications.

What did the GFORCE-1 study of MRT-8102 show?

+

Results released October 1, 2026 showed 88% of treated subjects with elevated cardiovascular risk reached CRP below 2 mg/L by week four, alongside reductions in IL-6, calprotectin (about 50% to 60%), HMGB1 and fibrinogen. NEK7 degradation was about 80% to 90%, and there were no serious adverse events. The stock fell in the following weeks despite the positive framing, and by November 20, 2026 it was about 13% below its October 16 close.

How has GLUE stock performed in 2026?

+

As of November 20, 2026 GLUE closed at about $8.71, down about 43% year to date, roughly 40% over three months and about 36% over one year, close to its 52-week low of about $8.63 and well below its high of about $25.77.

How did Monte Rosa do in its latest quarter?

+

In the third quarter of 2026, reported November 5, Monte Rosa posted collaboration revenue of about $54.4 million, up from about $12.8 million a year earlier, mostly from the $50 million Novartis milestone tied to the Sjogren's disease Phase 2 study. Net income was about $3.1 million, or $0.03 per share, against a consensus loss of about $0.20. Cash and investments fell to about $583 million from $626 million in June, mainly from operating spending.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Monte Rosa Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.